Archive · 11 Jun 2025
5 Indian Pharma CDMO Stocks Poised for Growth in 2025
Imagine companies that help make medicines.
These are CDMOs, which are like helpers for drug companies, taking care of things like making and packaging the drugs.
They help the drug companies focus on finding new medicines.
The article talks about 5 Indian companies that do this.
Some, like Divis Labs, make important ingredients.
Others, like Jubilant Pharmova, focus on injectable medicines.
Laurus Labs is growing fast.
These companies are expected to grow a lot because more drug companies need help making their products.
CDMOs offer drug development and manufacturing services to pharmaceutical companies.
The Indian CDMO market is projected to grow substantially by 2030.
Divis Laboratories specializes in custom synthesis and API manufacturing.
Jubilant Pharmova focuses on sterile injectables with expansion plans in North America.
Laurus Labs experiences rapid CDMO revenue growth with expanded capacity.
- Who
- Divis Laboratories, Jubilant Pharmova, Laurus Labs, Piramal Pharma, and Gland Pharma are the CDMO stocks discussed.
- What
- Article discusses 5 Indian pharma stocks that operate as CDMOs.
- When
- The article projects growth through 2030.
- Where
- Focus is on CDMOs based in India.
- Why
- CDMOs are expected to grow due to increased outsourcing and global demand.
- CDMO Definition
- Contract Development and Manufacturing Organisation
- Divis Labs Focus
- Custom synthesis and API manufacturing
- Jubilant Pharmova Focus
- Sterile injectables
- Laurus Labs Q4 CDMO Revenue Growth
- 85% YoY
- Piramal Pharma FY25 CDMO Revenue Growth
- Approximately 12% YoY
- Gland Pharma Business Model
- B2B (IP-led licensing, tech transfers, contract manufacturing)